Addex Therapeutics Ltd (SWX:ADXN)
Switzerland · Delayed Price · Currency is CHF 0.0220
+0.0002 (0.92%)
Oct 2, 2026, 2:41 PM CET
Addex Therapeutics Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 0.03 | 0.03 | 0.4 | 1.61 | 1.42 | 2.92 |
Other Revenue | 0.05 | 0.14 | 0.01 | 0 | 0.02 | 0.24 |
| 0.08 | 0.17 | 0.41 | 1.62 | 1.44 | 3.15 | |
Revenue Growth | -50.34% | -57.84% | -74.64% | 11.92% | -54.18% | -18.71% |
Cost of Revenue | 0.36 | 0.67 | 0.85 | 1.19 | 8.23 | 12.82 |
Gross Profit | -0.27 | -0.5 | -0.44 | 0.43 | -6.78 | -9.67 |
Selling, General & Admin | 2.33 | 2.32 | 2.31 | 2.67 | 3.76 | 5.84 |
Operating Expenses | 2.33 | 2.32 | 2.31 | 2.67 | 3.76 | 5.84 |
Operating Income | -2.6 | -2.81 | -2.76 | -2.24 | -10.54 | -15.51 |
Interest Expense | - | -0 | -0 | -0 | -0.03 | -0.06 |
Interest & Investment Income | 0.01 | - | 0.01 | 0.06 | 0.03 | 0.01 |
Earnings From Equity Investments | -4.26 | -4.01 | -2.18 | - | - | - |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0.02 | -0.32 | -0.26 | 0.21 |
EBT Excluding Unusual Items | -6.87 | -6.84 | -4.91 | -2.5 | -10.8 | -15.35 |
Pretax Income | -6.87 | -6.84 | -4.91 | -2.5 | -10.8 | -15.35 |
Earnings From Continuing Operations | -6.87 | -6.84 | -4.91 | -2.5 | -10.8 | -15.35 |
Earnings From Discontinued Operations | -0 | 0.11 | 11.97 | -8.06 | -10 | - |
Net Income | -6.87 | -6.73 | 7.06 | -10.56 | -20.8 | -15.35 |
Net Income to Common | -6.87 | -6.73 | 7.06 | -10.56 | -20.8 | -15.35 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 110 | 107 | 98 | 74 | 45 | 34 |
Shares Outstanding (Diluted) | 110 | 107 | 98 | 74 | 45 | 34 |
Shares Change | 5.13% | 9.44% | 32.04% | 64.45% | 32.43% | 27.88% |
EPS (Basic) | -0.06 | -0.06 | 0.07 | -0.14 | -0.46 | -0.45 |
EPS (Diluted) | -0.06 | -0.06 | 0.07 | -0.14 | -0.46 | -0.45 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2.39 | -2.17 | -5.37 | -8 | -16.44 | -14.74 |
Free Cash Flow Per Share | -0.02 | -0.02 | -0.06 | -0.11 | -0.36 | -0.43 |
Gross Margin | - | -288.55% | -108.35% | 26.62% | - | - |
Operating Margin | -3130.67% | -1628.25% | -671.94% | -138.70% | -729.50% | -491.74% |
Profit Margin | -8271.00% | -3892.31% | 1720.75% | -652.75% | -1439.78% | -486.85% |
Free Cash Flow Margin | -2873.12% | -1256.00% | -1310.80% | -494.64% | -1137.59% | -467.34% |
EBITDA | -2.6 | -2.81 | -2.56 | -2.23 | -10.53 | -15.16 |
EBITDA Margin | - | - | - | -137.97% | - | - |
D&A For EBITDA | -0 | 0 | 0.19 | 0.01 | 0.01 | 0.35 |
EBIT | -2.6 | -2.81 | -2.76 | -2.24 | -10.54 | -15.51 |
EBIT Margin | - | - | - | -138.70% | - | - |